NCT00881738View on ClinicalTrials.gov

To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

June 30, 2002

Study Completion Date

July 31, 2002

Conditions
Healthy
Interventions
DRUG

Clarithromycin 250 mg Tablets (Geneva, USA)

DRUG

Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)

Sponsors

Lead Sponsor

Sandoz
All Listed Sponsors
lead

Sandoz

INDUSTRY

NCT00881738 - To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter